保集健康年度报告2023

(Incorporated in the Cayman Islands with limited liability) Stock Code1246 ANNUAL REPORT2023 目錄Contents 97獨立核數師報告INDEPENDENT AUDITOR’S REPORT 2公司資料CORPORATE INFORMATION 105綜合損益及其他全面收益表CONSOLIDATED STATEMENT OF PROFITOR LOSS AND OTHER COMPREHENSIVEINCOME 4主席報告書CHAIRMAN’S STATEMENT 107綜合財務狀況表CONSOLIDATED STATEMENT OFFINANCIAL POSITION 7管理層討論及分析MANAGEMENT DISCUSSION ANDANALYSIS 109綜合權益變動表CONSOLIDATED STATEMENT OFCHANGES IN EQUITY 20董事及高級管理層履歷BIOGRAPHICAL DETAILS OFDIRECTORS AND SENIORMANAGEMENT 110綜合現金流量表CONSOLIDATED STATEMENT OF CASHFLOWS 25環境 、社會及管治報告ENVIRONMENTAL, SOCIAL ANDGOVERNANCE REPORT 112綜合財務報表附註NOTES TO THE CONSOLIDATEDFINANCIAL STATEMENTS 62企業管治報告CORPORATE GOVERNANCE REPORT 243五年財務概要FIVE YEARS FINANCIAL SUMMARY 83董事會報告DIRECTORS’ REPORT 公司資料Corporate Information BOARD OF DIRECTORS Executive Directors 裘東方先生（主席）（於二零二二年九月九日獲委任）虞一星女士（於二零二二年九月九日獲委任）張生海先生戴東行先生（於二零二二年九月九日退任） Mr. Qiu Dongfang(Chairman)(appointed on 9 September 2022) Ms. Yu Yixing (appointed on 9 September 2022)Mr. Zhang Sheng HaiMr. Dai Dong Xing (retired on 9 September 2022) Non-Executive Directors 崔光球先生邱斌先生（於二零二二年九月九日獲委任） Mr. Chui Kwong KauMr. Qiu Bin (appointed on 9 September 2022) Independent Non-Executive Directors 陳志強先生王先生易八賢先生（於二零二二年九月九日獲委任）許良偉先生（於二零二二年九月九日退任） Mr. Chan Chi Keung, BillyMr. Wang ZheMr. Yi Baxian (appointed on 9 September 2022)Mr. Xu Liang Wei (retired on 9 September 2022) BOARD COMMITTEES Audit Committee 陳志強先生（主席）王先生邱斌先生 Mr. Chan Chi Keung, Billy(Chairman)Mr. Wang ZheMr. Qiu Bin Nomination Committee 裘東方先生（主席）易八賢先生王先生 Mr. Qiu Dongfang(Chairman)Mr. Yi BaxianMr. Wang Zhe Remuneration Committee 易八賢先生（主席）虞一星女士王先生 Mr. Yi Baxian(Chairman)Ms. Yu YixingMr. Wang Zhe 伍鑒明先生 COMPANY SECRETARY Mr. Ng Kam Ming AUTHORISED REPRESENTATIVES 裘東方先生（於二零二二年九月九日獲委任）伍鑒明先生戴東行先生（於二零二二年九月九日退任） Mr. Qiu Dongfang (appointed on 9 September 2022)Mr. Ng Kam MingMr. Dai Dong Xing (retired on 9 September 2022) REGISTERED OFFICE Windward 3,Regatta Office ParkPO Box 1350Grand Cayman KY1-1108Cayman Islands Windward 3,Regatta Office ParkPO Box 1350Grand Cayman KY1-1108Cayman Islands Annual Report 20232 公司資料Corporate Information AUDITOR 香港立信德豪會計師事務所有限公司執業會計師香港干諾道中111號永安中心25樓 BDO LimitedCertified Public AccountantsFloor 25, Wing On Centre111 Connaught Road CentralHong Kong LEGAL ADVISER 盛德律師事務所香港中環國際金融中心二期39樓 Sidley Austin39/F, Two Int’l Finance CentreCentral, Hong Kong H E A D O F F I C E A N D P R I N C I P A L P L A C E O FBUSINESS IN HONG KONG Room 2101, 21/F, Wing On CentreNo. 111 Connaught Road CentralHong Kong 香港干諾道中111號永安中心21樓2101室 PRINCIPAL SHARE REGISTRAR AND TRANSFEROFFICE Ocorian Trust (Cayman) LimitedWindward 3,Regatta Office ParkPO Box 1350Grand Cayman KY1-1108Cayman Islands Ocorian Trust (Cayman) LimitedWindward 3,Regatta Office ParkPO Box 1350Grand Cayman KY1-1108Cayman Islands HONG KONG BRANCH SHARE REGISTRAR ANDTRANSFER OFFICE 卓佳證券登記有限公司香港夏愨道16號遠東金融中心17樓 Tricor Investor Services Limited17/F, Far East Finance Centre16 Harcourt RoadHong Kong PRINCIPAL BANKERS 中國銀行（香港）有限公司招商永隆銀行有限公司 Bank of China (Hong Kong) LimitedCMB Wing Lung Bank Limited STOCK CODE 1246（香港聯合交易所有限公司主板） 1246 (Main Board of The Stock Exchange of Hong Kong Limited) WEBSITE www.boillhealthcare.com.hk www.boillhealthcare.com.hk 主席報告書Chairman’s Statement 各位股東： Dear Shareholders, 本人謹代表保集健康控股有限公司（「」）及其附屬公司（統稱「」）董事（「」）會（「」）欣然向本公司股東（「」）提呈本集團截至二零二三年三月三十一日止財政年度（「」）之經審核全年綜合業績 。 On behalf of the board (“Board”) of directors (“Director(s)”) ofBoill Healthcare Holdings Limited (“Company”) and its subsidiaries(collectively the “Group”), I am pleased to present the annualaudited consolidated results of the Group for the financial yearended 31 March 2023 (“FY2023”) to the shareholders of theCompany (the “Shareholders”). 於 二 零 二 三 財 年 ， 本 集 團 之 收 益（ 包 括 已 終 止經 營 業 務 ）約 為355.4百 萬 港 元 ， 較 截 至 二 零二二年三月三十一日止年度（「」）的約1,016.2百萬港元減少約660.8百萬港元或65.0%。二零二三財年 ，物業發展的收益為約348.3百萬港元（二零二二財年：約1,004.6百萬港元）。 The Group’s revenue (including discontinued operation) for FY2023was approximately HK$355.4 million, representing a decreaseof approximately HK$660.8 million or 65.0% from approximatelyHK$1,016.2 million for the year ended 31 March 2022 (“FY2022”).T h e r e v e n u e f r o m t h e p r o p e r t y d e v e l o p m e n t f o r F Y2 0 2 3was approximately HK$348.3 million (FY2022: approximatelyHK$1,004.6 million). 於二零二三財年 ，本公司擁有人應佔虧損（包括已終止經營業務）為約428.3百萬港元（二零二二財年：約517.8百萬港元），而本公司擁有人應佔每股基本及攤薄虧損為約31.54港仙（二零二二財年：38.13港仙）。 The loss attributable to owners of the Company (includingdiscontinued operation) for FY2023 was approximately HK$428.3million (FY2022: approximately HK$517.8 million), while the basicand diluted loss per share attributable to owners of the Companywas approximately HK31.54 cents (FY2022: HK38.13 cents). 於二零二二財年 ，上海保賢實業有限公司（「」，本公司非全資附屬公司）收購位於中華人民共和國（「」）奉賢區工業綜合開發區12A-01A號地塊之總地盤面積約63,481平方米之土地地塊（「e」）（東至滬杭公路 、西至人傑路 、南至奉浦大道 、北至芝江路）（「」）之土地使用權 。 During FY2022, Shanghai Baoxian Industrial Co., Ltd. (a non-whollyowned subsidiar